Cha Charles, DeMatteo Ronald P, Blumgart Leslie H
Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S130-7. doi: 10.1097/00004836-200211002-00009.
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, responsible for an estimated one million deaths annually. The incidence in the United States has steadily increased over the past two decades. Although HCC has historically had a dismal prognosis, it is now being detected earlier as a result of improved radiologic imaging and surveillance. This affords the opportunity to treat patients with curative intent, and may improve survival. Partial hepatectomy and transplantation each provide potentially curative therapy for selected patients with HCC. Transplantation is indicated when there is severe underlying liver dysfunction. Local ablative therapy, such as ethanol injection, hepatic artery embolization, and radiofrequency ablation, offer palliation for patients when surgery is not feasible. The rational application of the myriad of therapies to a patient with HCC is designed to maximize both quality of life and survival.
肝细胞癌（HCC）是全球最常见的恶性肿瘤之一，估计每年导致100万人死亡。在过去二十年中，美国的发病率稳步上升。尽管HCC历来预后不佳，但由于放射影像学和监测的改善，现在能够更早地检测到。这为以治愈为目的治疗患者提供了机会，并可能提高生存率。部分肝切除术和肝移植分别为选定的HCC患者提供了潜在的治愈性治疗方法。当存在严重的潜在肝功能不全时，建议进行肝移植。局部消融治疗，如乙醇注射、肝动脉栓塞和射频消融，在手术不可行时为患者提供姑息治疗。对HCC患者合理应用多种治疗方法旨在最大限度地提高生活质量和生存率。
